[go: up one dir, main page]

TWI372620B - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
TWI372620B
TWI372620B TW099117063A TW99117063A TWI372620B TW I372620 B TWI372620 B TW I372620B TW 099117063 A TW099117063 A TW 099117063A TW 99117063 A TW99117063 A TW 99117063A TW I372620 B TWI372620 B TW I372620B
Authority
TW
Taiwan
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
TW099117063A
Other languages
English (en)
Other versions
TW201034659A (en
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW201034659A publication Critical patent/TW201034659A/zh
Application granted granted Critical
Publication of TWI372620B publication Critical patent/TWI372620B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW099117063A 2005-09-09 2006-09-08 Treatment of autoimmune diseases TWI372620B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (2)

Publication Number Publication Date
TW201034659A TW201034659A (en) 2010-10-01
TWI372620B true TWI372620B (en) 2012-09-21

Family

ID=37056992

Family Applications (2)

Application Number Title Priority Date Filing Date
TW099117063A TWI372620B (en) 2005-09-09 2006-09-08 Treatment of autoimmune diseases
TW095133326A TWI376223B (en) 2005-09-09 2006-09-08 Treatment of autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW095133326A TWI376223B (en) 2005-09-09 2006-09-08 Treatment of autoimmune diseases

Country Status (28)

Country Link
US (1) US20080200438A1 (zh)
EP (2) EP2295049B1 (zh)
JP (4) JP5244598B2 (zh)
KR (3) KR20140117704A (zh)
CN (1) CN101257899B (zh)
AT (1) ATE489948T1 (zh)
AU (2) AU2006289100B2 (zh)
BR (1) BRPI0615906A2 (zh)
CA (2) CA2820510A1 (zh)
CY (1) CY1111285T1 (zh)
DE (1) DE602006018629D1 (zh)
DK (2) DK2295049T3 (zh)
ES (2) ES2529724T3 (zh)
IL (2) IL189665A (zh)
JO (1) JO2655B1 (zh)
MA (1) MA29787B1 (zh)
MX (1) MX2008003170A (zh)
NO (1) NO20081727L (zh)
NZ (2) NZ566137A (zh)
PL (2) PL2295049T3 (zh)
PT (2) PT2295049E (zh)
RU (2) RU2424795C2 (zh)
SG (1) SG165364A1 (zh)
SI (2) SI1926483T1 (zh)
TN (1) TNSN08103A1 (zh)
TW (2) TWI372620B (zh)
WO (1) WO2007028821A2 (zh)
ZA (1) ZA200801694B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
ES2563034T3 (es) 2004-10-12 2016-03-10 Kyorin Pharmaceutical Co., Ltd. Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos
EP1932522B1 (en) * 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
HRP20131172T1 (hr) * 2006-08-08 2014-01-17 Kyorin Pharmaceutical Co., Ltd. Esterski derivat aminofosforne kiseline i modulator receptora s1p koji sadrži isti kao aktivni sastojak
US20100093745A1 (en) * 2007-02-13 2010-04-15 Kazuhiko Kuriyama Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
MY154685A (en) * 2008-05-20 2015-07-15 Kyorin Seiyaku Kk Agent for maintanance of induced remission
CN102119028A (zh) * 2008-08-18 2011-07-06 诺瓦提斯公司 用于治疗脱髓鞘性周围神经病的氨基醇衍生物
MX2012012926A (es) * 2010-05-06 2012-12-17 Novartis Ag Tratamiento de enfermedades autoinmunes.
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
BRPI0212894B8 (pt) * 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
KR101095807B1 (ko) * 2002-09-24 2011-12-21 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
WO2004028512A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage form with two cores
SI1602660T1 (sl) * 2003-02-18 2011-06-30 Kyorin Seiyaku Kk Derivati aminofosfonske kisline, njihove adicijske soli in modulatorji receptorja za S1P
DE602004017847D1 (de) * 2003-04-08 2009-01-02 Novartis Ag Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
AU2004268052B2 (en) * 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
ES2495690T3 (es) * 2004-11-29 2014-09-17 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL2295049T3 (pl) 2015-04-30
JP2013010802A (ja) 2013-01-17
JP2009507810A (ja) 2009-02-26
DK2295049T3 (en) 2015-02-23
EP1926483B1 (en) 2010-12-01
KR20080046231A (ko) 2008-05-26
JO2655B1 (en) 2012-06-17
IL189665A (en) 2014-07-31
PT1926483E (pt) 2011-03-03
IL233328A0 (en) 2014-08-31
SG165364A1 (en) 2010-10-28
CN101257899A (zh) 2008-09-03
MX2008003170A (es) 2008-03-18
AU2006289100B2 (en) 2010-07-22
MA29787B1 (fr) 2008-09-01
CY1111285T1 (el) 2015-08-05
JP2017019854A (ja) 2017-01-26
SI1926483T1 (sl) 2011-04-29
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
TNSN08103A1 (en) 2009-07-14
WO2007028821A2 (en) 2007-03-15
RU2011111117A (ru) 2012-09-27
AU2010224355A1 (en) 2010-10-14
KR20140117704A (ko) 2014-10-07
EP1926483A2 (en) 2008-06-04
ES2529724T3 (es) 2015-02-25
IL189665A0 (en) 2008-06-05
AU2006289100A1 (en) 2007-03-15
DK1926483T3 (da) 2011-03-14
KR20140019033A (ko) 2014-02-13
PL1926483T3 (pl) 2011-05-31
RU2493840C2 (ru) 2013-09-27
TW200803829A (en) 2008-01-16
TW201034659A (en) 2010-10-01
PT2295049E (pt) 2015-03-02
BRPI0615906A2 (pt) 2011-05-31
CA2820510A1 (en) 2007-03-15
ATE489948T1 (de) 2010-12-15
RU2424795C2 (ru) 2011-07-27
CA2620554A1 (en) 2007-03-15
HK1149906A1 (zh) 2011-10-21
DE602006018629D1 (de) 2011-01-13
ES2357426T3 (es) 2011-04-26
SI2295049T1 (sl) 2015-03-31
KR101476451B1 (ko) 2014-12-24
NO20081727L (no) 2008-06-06
JP2015025002A (ja) 2015-02-05
EP2295049A1 (en) 2011-03-16
ZA200801694B (en) 2009-09-30
NZ588372A (en) 2012-03-30
JP6077265B2 (ja) 2017-02-08
NZ566137A (en) 2011-05-27
CN101257899B (zh) 2012-10-03
RU2008113187A (ru) 2009-10-20
CA2620554C (en) 2013-12-17
AU2010224355B2 (en) 2012-03-29
EP2295049B1 (en) 2014-11-26
JP5244598B2 (ja) 2013-07-24
WO2007028821A3 (en) 2007-05-03
TWI376223B (en) 2012-11-11

Similar Documents

Publication Publication Date Title
IL233328A0 (en) Treatment of autoimmune diseases
TW200509892A (en) Novel aminobenzophenone compounds
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
SG163517A1 (en) Antiviral compounds and methods
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
DE602006016449D1 (zh)
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos
MX2007003281A (es) N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees